- Home
- CEE vs KZR Comparison
CEE vs KZR Comparison
Compare CEE & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- KZR
- Stock Information
- Founded
- CEE 1990
- KZR 2015
- Country
- CEE Germany
- KZR United States
- Employees
- CEE N/A
- KZR N/A
- Industry
- CEE Finance Companies
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- KZR Health Care
- Exchange
- CEE Nasdaq
- KZR Nasdaq
- Market Cap
- CEE 75.8M
- KZR 65.3M
- IPO Year
- CEE N/A
- KZR 2018
- Fundamental
- Price
- CEE $12.14
- KZR $7.62
- Analyst Decision
- CEE
- KZR Hold
- Analyst Count
- CEE 0
- KZR 2
- Target Price
- CEE N/A
- KZR $20.00
- AVG Volume (30 Days)
- CEE 22.0K
- KZR 72.5K
- Earning Date
- CEE 01-01-0001
- KZR 11-12-2024
- Dividend Yield
- CEE 3.86%
- KZR N/A
- EPS Growth
- CEE N/A
- KZR N/A
- EPS
- CEE N/A
- KZR N/A
- Revenue
- CEE N/A
- KZR N/A
- Revenue This Year
- CEE N/A
- KZR N/A
- Revenue Next Year
- CEE N/A
- KZR $66.68
- P/E Ratio
- CEE N/A
- KZR N/A
- Revenue Growth
- CEE N/A
- KZR N/A
- 52 Week Low
- CEE $7.80
- KZR $5.20
- 52 Week High
- CEE $10.32
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- CEE 61.19
- KZR 53.01
- Support Level
- CEE $11.50
- KZR $7.21
- Resistance Level
- CEE $12.31
- KZR $7.65
- Average True Range (ATR)
- CEE 0.51
- KZR 0.26
- MACD
- CEE -0.02
- KZR -0.01
- Stochastic Oscillator
- CEE 55.83
- KZR 95.71
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.